Arvinas (NASDAQ: ARVN) is one of 548 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its rivals? We will compare Arvinas to similar companies based on the strength of its profitability, valuation, dividends, earnings, analyst recommendations, risk and institutional ownership.
This is a summary of current ratings and recommmendations for Arvinas and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
This table compares Arvinas and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation & Earnings
This table compares Arvinas and its rivals gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Arvinas||$14.32 million||-$41.48 million||-0.90|
|Arvinas Competitors||$2.15 billion||$228.73 million||-3.52|
Arvinas’ rivals have higher revenue and earnings than Arvinas. Arvinas is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Insider & Institutional Ownership
41.1% of Arvinas shares are held by institutional investors. Comparatively, 46.3% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 31.8% of Arvinas shares are held by company insiders. Comparatively, 14.9% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Arvinas beats its rivals on 7 of the 12 factors compared.
Arvinas Holding Company, LLC, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110, proteolysis targeting chimeras (PROTAC) targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of women with metastatic ER+ breast cancer. The company is also developing other PROTACs for degrading AR and other clinically relevant AR point mutations; and various other products for the treatment of neurodegenerative diseases, including tauopathies. Arvinas Holding Company, LLC was founded in 2015 and is based in New Haven, Connecticut.
Receive News & Ratings for Arvinas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arvinas and related companies with MarketBeat.com's FREE daily email newsletter.